AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2021
Dec 6, 2021
31542_dirs_2021-12-06_25753ff8-f384-4274-a8fc-410c49f2644b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2021-12-03
Reporting Person: Miller Steve (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-03 | Common stock, par value $0.001 per share | M | 20000 | — | Acquired | 761724 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-03 | Restricted Stock Units | $ | M | 20000 | Disposed | Common Stock (20000) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022.
F3: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 3, 2021.
More from CATALYST PHARMACEUTICALS, INC.
M&A Activity
2026
Jun 8
Report Publication Announcement
2026
May 11
M&A Activity
2026
May 7
Major Shareholding Notification
2026
Mar 26
Earnings Release
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6